Skip to main content
OpenTrials
Completed

NCT Number: NCT03188900

Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Preeclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pre-Eclampsia Pregnancy Complications Urogenital Diseases

Age range

18 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Hopital Cochin

Paris, 75014, France

About this study

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) :

  • Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP
  • Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP
  • Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP
  • Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP
  • Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 18 to 50 years old
  • Singleton pregnancies between 20 and 41 weeks of gestation
  • Preeclampsia
  • Normal pregnancy

Exclusion criteria

  • Age<18
  • Infectious disease: HIV, HBV or HCV
  • Multiple pregnancies
  • Opposition of the patient

Treatment and study plan

A collection of maternal plasma and serum

Biological

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)

Primary outcomes

  1. ratio sFlt-1/PlGF

    Time frame: Day 0

    measurement of of sFlT-1 and PlGF

Secondary outcomes

  1. Kinetics of these ratios sFlt-1/PlGF during pregnancy

    Time frame: until 5 month

    measurement of of sFlT-1 and PlGF at many times

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • INSERM UMR-S 1139
  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

Acronym: APHERESE

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jun 16, 2017
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.